Doubled down on ATNX at $5.32.
The company is down 50% today based on quarterly results and FDA rejection of their drug. However:
1. the company still has room to fight the decision
2. the company has a portfolio of other products to support its revenue
3. the company has a pipeline of other drugs in development.
Here is the link to my original analysis: